Tomás José González-López1, María Teresa Alvarez-Román2, Cristina Pascual3, Blanca Sánchez-González4, Fernando Fernández-Fuentes5, Isidro Jarque6, Gloria Pérez-Rus3, Susana Pérez-Crespo7, Silvia Bernat8, José Angel Hernández-Rivas9, Marcio M Andrade10, Montserrat Cortés11, Marta Gómez-Nuñez12, Pavel Olivera13, Violeta Martínez-Robles14, Angeles Fernández-Rodríguez15, Miguel Angel Fuertes-Palacio16, Carmen Fernández-Miñano17, Erik de Cabo18, Rosa Fisac19, Carlos Aguilar20, Abelardo Bárez21, María Jesús Peñarrubia22, Luis Javier García-Frade23, José Ramón González-Porras24. 1. Department of Hematology, Hospital Universitario de Burgos, Burgos, Spain. 2. Department of Hematology, Hospital Universitario La Paz, Madrid, Spain. 3. Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. 4. Department of Hematology, Hospital del Mar, Barcelona, Spain. 5. Department of Hematology, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain. 6. Department of Hematology, Hospital Universitario La Fé, Valencia, Spain. 7. Department of Hematology, Hospital de Santiago de Compostela, Santiago de Compostela (La Coruña), Spain. 8. Department of Hematology, Hospital de La Plana, Castellón, Spain. 9. Department of Hematology, Hospital Infanta Leonor, Madrid, Spain. 10. Department of Hematology, Hospital Universitario Miguel Servet, Zaragoza, Spain. 11. Department of Hematology, Fundació Hospital Asil de Granollers, Granollers (Barcelona), Spain. 12. Department of Hematology, Hospital Parc Taulí, Sabadell (Barcelona), Spain. 13. Department of Hematology, Hospital Universitario Vall de Hebron, Barcelona, Spain. 14. Department of Hematology, Hospital de León, León, Spain. 15. Department of Hematology, Hospital Universitario Central de Asturias, Oviedo (Asturias), Spain. 16. Department of Hematology, Hospital Clínico Lozano Blesa, Zaragoza, Spain. 17. Department of Hematology, Hospital Vega Baja, Orihuela (Alicante), Spain. 18. Department of Hematology, Hospital del Bierzo, Ponferrada (León), Spain. 19. Department of Hematology, Hospital de Segovia, Segovia, Spain. 20. Department of Hematology, Hospital de Soria, Soria, Spain. 21. Department of Hematology, Hospital de Avila, Avila, Spain. 22. Department of Hematology, Hospital Clínico de Valladolid, Valladolid, Spain. 23. Department of Hematology, Hospital Universitario Río Hortega, Valladolid, Spain. 24. Department of Hematology, IBSAL-Hospital Universitario de Salamanca, Salamanca, Spain.
Abstract
BACKGROUND: Eltrombopag is effective and safe in chronic immune thrombocytopenia (ITP). However, clinical trials may not accurately reflect what happens in clinical practice. We evaluated the efficacy and safety of eltrombopag in primary chronic ITP in a real-world setting. METHODS: A total of 164 primary patients with chronic ITP from 40 Spanish centers, who had been treated with eltrombopag, were retrospectively evaluated. RESULTS: The median age of our cohort (72% women) was 63 yr (interquartile range, IQR, 45-75 yr). The median time with ITP diagnosis was 81 months (IQR, 30-192 months). The median number of therapies prior to eltrombopag was 3 (IQR, 2-4). At the time of eltrombopag start, 45 patients (30%) were receiving concomitant treatment for ITP. Forty-six patients (30%) had bleeding signs/symptoms the month before the treatment started. The median platelet count at eltrombopag initiation was 22 × 10(9) /L (IQR, 8-39 × 10(9) /L). A total of 135 patients (88.8%) achieved a platelet response. The median time to platelet response was 12 d (95% CI, 9-13 d). Maintained platelet response rate during the 15-month period under examination was 75.2%. Twenty-eight patients (18.4%) experienced adverse events, mainly grades 1-2. CONCLUSION: Eltrombopag is highly effective and well tolerated in unselected patients with primary chronic ITP.
BACKGROUND:Eltrombopag is effective and safe in chronic immune thrombocytopenia (ITP). However, clinical trials may not accurately reflect what happens in clinical practice. We evaluated the efficacy and safety of eltrombopag in primary chronic ITP in a real-world setting. METHODS: A total of 164 primary patients with chronic ITP from 40 Spanish centers, who had been treated with eltrombopag, were retrospectively evaluated. RESULTS: The median age of our cohort (72% women) was 63 yr (interquartile range, IQR, 45-75 yr). The median time with ITP diagnosis was 81 months (IQR, 30-192 months). The median number of therapies prior to eltrombopag was 3 (IQR, 2-4). At the time of eltrombopag start, 45 patients (30%) were receiving concomitant treatment for ITP. Forty-six patients (30%) had bleeding signs/symptoms the month before the treatment started. The median platelet count at eltrombopag initiation was 22 × 10(9) /L (IQR, 8-39 × 10(9) /L). A total of 135 patients (88.8%) achieved a platelet response. The median time to platelet response was 12 d (95% CI, 9-13 d). Maintained platelet response rate during the 15-month period under examination was 75.2%. Twenty-eight patients (18.4%) experienced adverse events, mainly grades 1-2. CONCLUSION:Eltrombopag is highly effective and well tolerated in unselected patients with primary chronic ITP.
Authors: Tomás José González-López; Fernando Fernández-Fuertes; José Angel Hernández-Rivas; Blanca Sánchez-González; Violeta Martínez-Robles; María Teresa Alvarez-Román; Gloria Pérez-Rus; Cristina Pascual; Silvia Bernat; Esther Arrieta-Cerdán; Carlos Aguilar; Abelardo Bárez; María Jesús Peñarrubia; Pavel Olivera; Angeles Fernández-Rodríguez; Erik de Cabo; Luis Javier García-Frade; José Ramón González-Porras Journal: Int J Hematol Date: 2017-06-30 Impact factor: 2.490
Authors: Drew Provan; Donald M Arnold; James B Bussel; Beng H Chong; Nichola Cooper; Terry Gernsheimer; Waleed Ghanima; Bertrand Godeau; Tomás José González-López; John Grainger; Ming Hou; Caroline Kruse; Vickie McDonald; Marc Michel; Adrian C Newland; Sue Pavord; Francesco Rodeghiero; Marie Scully; Yoshiaki Tomiyama; Raymond S Wong; Francesco Zaja; David J Kuter Journal: Blood Adv Date: 2019-11-26
Authors: Andris Skride; Matiss Sablinskis; Kristaps Sablinskis; Sandra Lejniece; Aivars Lejnieks; Walter Klepetko; Irene M Lang Journal: Am J Case Rep Date: 2018-10-19